Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Josep Brugada
The Brugada syndrome is an inherited cardiac arrhythmia disorder caused by mutations in the cardiac sodium channel gene SCN5A.
Carriers of the disease may develop a variety of cardiac arrhythmias including supraventricular tachycardias, AV conduction defects or block, sick sinus syndrome with atrial standstill, ventricular tachycardia and ventricular fibrillation.
The disease is characterised by the lack of structural heart disease and an ECG with a characteristic coved-type ST segment elevation in leads V1, V2 and V3. Syncopal episodes and paroxysmal palpitations are the only symptoms attributable to the disease that may act as a warning before (aborted) sudden arrhythmic death occurs. General agreement exists that an implantable cardioverter defibrillator must be given to patients with the Brugada syndrome resuscitated from ventricular fibrillation.
However, controversy exists on how to approach the individual with a Brugada-like ECG who has never developed ventricular fibrillation.
For 12 years now we have been maintaining a large data base of individuals and patients with a diagnostic Brugada-like ECG.
At the last follow-up we analysed the status of 724 individuals of whom 547 (75%) had no previous cardiac arrest. A subgroup of 167 asymptomatic individuals was also identified who had no family history of sudden death, or Brugada syndrome and were considered fortuitous, isolated cases.
Of the 167 fortuitous cases with a Brugada-like ECG, 11 (6.5%) developed (aborted) sudden death. In these non-familial asymptomatic individuals the best predictor of spontaneous ventricular fibrillation was the inducibility of a sustained arrhythmia during programmed ventricular stimulation (p<0.008). Fortuitous cases studied by programmed ventricular stimulation and inducible stimulation usually received an implantable defibrillator and survived when ventricular fibrillation occurred (6 individuals). There were 5 effective sudden deaths in the 167 fortuitous cases.
None of the 5 had had an electrophysiological study done and none had had a defibrillator implanted (see example in figure 1). For the whole group without previous cardiac arrest, logistic regression analysis showed that a previous history of syncope carries a sufficient risk of (aborted) sudden death (1.2 to 27.2% at 3 years follow-up) such as to recommend an implantable defibrillator independently from the results of programmed ventricular stimulation.
In asymptomatic individuals (including the fortuitous, non-familial cases) programmed ventricular stimulation helps to stratify the risk of (aborted) sudden death and to identify candidates to prophylactic treatment, the hazard ratio of inducible individuals being 8.33 (95% confidence intervals 2.8-25.0) as compared to the non-inducible ones. Figure 1. 34 years old male, asymptomatic, no family history, routine ECG. Echocardio normal, Holter normal, stress test normal. EPS advised, refused by the patient. Eight months later: sudden arrhythmic death at 1 a.m., VF when EMS arrives. Necropsy: normal heart, normal coronary arteries. No other cause for sudden death: probably arrhythmic
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter report. J Am Coll Cardiol 1992; 20:1391-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1309182 2. Brugada J, Brugada R, Brugada P. Right bundle branch block and ST segment elevation in leads V1 through V3. A marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998;97:457-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9490240 3. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000;101:510-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10662748 4. BrugadaP, Geelen P, Brugada R, et al. Prognostic value of electrophysiologic investigations in Brugada syndrome. J Cardiovasc Electrophysiol 2001;12:1004-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11573688 5. Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 2002; 105:73-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11772879